Unusual presentation of extranodal diffuse large B-cell lymphoma in a solid-organ recipient during long-term immunosuppressive treatment.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Marrow
/ pathology
Cyclophosphamide
/ therapeutic use
Disease Management
Disease Susceptibility
Doxorubicin
/ therapeutic use
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunohistochemistry
/ methods
Immunosuppressive Agents
/ adverse effects
Kidney
/ pathology
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Organ Transplantation
/ adverse effects
Positron Emission Tomography Computed Tomography
Prednisone
/ therapeutic use
Spleen
/ pathology
Symptom Assessment
Treatment Outcome
Vincristine
/ therapeutic use
Extranodal diffuse large B-cell lymphoma
PET/CT
kidney transplantation
posttransplant lymphoproliferative disorders
solid organ recipient
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
24
8
2021
medline:
15
12
2021
entrez:
23
8
2021
Statut:
ppublish
Résumé
Posttransplant lymphoproliferative disorders (PTLDs) refer to a group of diseases, including diffuse large B-cell lymphoma (DLBCL), that develop after solid organ transplantation or hematopoietic stem cell transplantation. Extranodal involvement in PTLDs is common. Reports about exclusive bone marrow involvement are rare. A 70-year-old woman, who had undergone kidney transplantation in 2018, was diagnosed with exclusively extranodal, Epstein-Barr virus-negative DLBCL, with bone marrow and spleen involvement, during long-term immunosuppression. She achieved complete remission with combined immunochemotherapy and temporary hold of immunosuppression. This case shows an uncommon clinical presentation of DLBCL, which was challenging to diagnose, being entirely extranodal. The favorable clinical course relied on timely diagnosis and a multidisciplinary approach. Long-term consequences of posttransplant immunosuppression require a high level of suspicion for an appropriate management, aimed at preserving the graft while eradicating the lymphoproliferative disorder.
Identifiants
pubmed: 34423702
doi: 10.1177/03008916211040862
doi:
Substances chimiques
Immunosuppressive Agents
0
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM